Sitemap
Main menu
- Home
- SMA
- Basic research
- Drug discovery
- Clinical research
- Stem cells
- News
- Researchers demonstrate efficacy of antisense therapy for spinal muscular atrophy
- Gene therapy rescues mice with SMA
- Isis Pharmaceuticals towards an antisense drug
- New finding clarifies the cause of SMA
- Trans-splicing and gene therapy
- Strengthening the junctions
- New European funding for SMA research
- New publications on SMA
- Isis Pharmaceuticals develops a spinal muscular atrophy drug
- Motorgraft receives orphan drug designation
- EIM effective as a diagnosis tool for SMA
- Repligen and quinazoline for a SMA treatment
- A drug candidate for SMA: PTK-SMA1
- Significant progress towards moving novel therapy into human clinical trials
- The National Convention Asamsi-Famiglie SMA
- Drug treatment with VPA in SMA1 infants
- A SMA positive modifier in the SMN2 gene
- An Italian Registry for SMA patients
- Orphan Drug designation for Quinazoline495
- A new drug candidate for SMA therapy
- Two research projects funded by Telethon
- Families of SMA therapeutic pipeline
- Antisense therapy against SMA
- A translational research on spinal muscular atrophy
- SMA at AAN Annual Meeting
- The prevention of SMA
- New paper published on SMA clinical trial
- PTC Therapeutics and SMA Foundation Collaboration
- Towards potential stem cell therapy
- New light on spinal muscular atrophy genetics
- New clinical trial on adult SMA III patients
- Completion of Biomarkers trial enrollment
- European grants for SMA Research Projects
- Trophos and AFM: together against SMA
- New grants FSMA 2009 for SMA eradication
- New safer way developed to generate iPS cells
- Electrically active motor neurons from iPS cells
- Resveratrol and spinal muscular atrophy
- Continuing studies on a-SMN
- New SMA research published in the Journal of Neuroscience
- Tetracycline derivative program goes on
- Confirmation on C5-quinazoline activity
- Towards the trial with the stem!
- Scientists advance SMA research with stem cells
- Successful trial with Trophos
- A study on follistatin
- Molecular therapy for SMA
- SAPRE and SMA1
- Gene therapy on mice SMA
- Biomarkers for SMA
- International SMA Patient Registry launches new website
- Protein linked to SMA identified
- Important news on the causes of SMA
- FSMA program and Paratek
- Gene repair strategy explored in SMA
- A trial with Trophos
- Contacts
- Links
- Sitemap
- Newsletter
- Download
Menu top
Resources
Concepts
Disclaimer
This site is aimed at everyone involved in the fight against spinal muscular atrophy, whether patients and their families, physicians, health professionals or students of the area. The information in this site serves to enhance, not replace, the doctor-patient relationship.
Note on site manager
Note on sources
LAST UPDATE: July 25, 2010
No advertising on this site!
CAUTION Medical contents on the site are purely for guidance and information and cannot replace in any case the medical advice.
All contents provided by the site are written exclusively by professionals in the medical-scientific area, unless an explicit statement does not specify otherwise.This site is dedicated to the memory of Federico Milcovich and all the people who died prematurely due to spinal muscular atrophy and other neuromuscular diseases.
Breaking news
- - Researchers demonstrate efficacy of antisense therapy for spinal muscular atrophy
- - Gene therapy rescues mice with SMA
- - Isis Pharmaceuticals towards an antisense drug
- - New finding clarifies the cause of SMA
- - Trans-splicing and gene therapy
- - Strengthening the junctions
- - New European funding for SMA research
- - New publications on SMA
Main menu
Certification
This site complies with
the HONcode standard
for trustworthy health
information: verify here.
Concepts
Resources
Login
Polls
Adobe Reader
If you need Adobe PDF reader
download it from here:
Home / SMA / News / Basic research / Drug discovery / Clinical research / Stem cells / Link / Download / Contacts
/ © Incipit